Lincoln Pharmaceuticals on Thursday reported a nearly 17% growth in net profit to Rs 27.70 crore for the April-June quarter as compared to Rs 23.69 crore in the same quarter of the last fiscal.
Total income rose by 7.3% to Rs 169.34 crore in the first quarter of FY26 compared to Rs 157.69 crore in the year-ago period, the company said in a statement.
“EBITDA for Q1 FY26 was reported at Rs 39.08 crore as compared to EBITDA of Rs 33.14 crore in Q1 FY25, growth of 17.92% Y-o-Y,” the statement said.
The company is targeting a revenue of Rs 1,000 crore within the next three years, driven by business expansion into high-value product lines and entry into new markets, Lincoln Pharmaceuticals Managing Director Mahendra Patel said.
This goal is part of a broader strategy to achieve a 15-18% annual growth rate, driven by strong performance in the cardiac, diabetic, dermatology, and ENT segments, Patel added.
During the first quarter, the company started its bulk drug manufacturing plant, he said, adding that the company has received approvals for 10 products and others are under process. The company has invested Rs 4 crore for this plant from internal accruals.
Shares of the company jumped by 8.47% to close at at Rs 576.90 apiece on BSE.
